Assessment of a Chemotherapy Response Score (CRS) System for Tubo-Ovarian High-Grade Serous Carcinoma (HGSC)
暂无分享,去创建一个
R. Berkowitz | W. Welch | B. Quade | C. Feltmate | M. Muto | M. Nucci | M. Hirsch | D. Lin | U. Matulonis | C. Crum | N. Horowitz | G. Mutter | J. Hecht | P. Konstantinopoulos | Emily E. K. Meserve | Joyce F. Liu | B. Howitt | K. Strickland | Mamta Gupta | K. Jochumsen | E. Stover | Kenneth R. Lee | H. Ditzel
[1] P. Dey,et al. The chemotherapy response score is a useful histological predictor of prognosis in high‐grade serous carcinoma , 2018, Histopathology.
[2] Young Tae Kim,et al. External validation of chemotherapy response score system for histopathological assessment of tumor regression after neoadjuvant chemotherapy in tubo-ovarian high-grade serous carcinoma , 2017, Journal of gynecologic oncology.
[3] M. Bulsara,et al. Prognostic Role of Histological Tumor Regression in Patients Receiving Neoadjuvant Chemotherapy for High-Grade Serous Tubo-ovarian Carcinoma , 2017, International Journal of Gynecologic Cancer.
[4] C. Holschneider,et al. Complete Pathologic Response at Interval Debulking Surgery Following Neoadjuvant Chemotherapy Predicts Improved Survival in Women with Advanced Epithelial Ovarian Cancer in a Multi-institutional Cohort , 2016 .
[5] C. Gilks,et al. The Chemotherapy Response Score (CRS): Interobserver Reproducibility in a Simple and Prognostically Relevant System for Reporting the Histologic Response to Neoadjuvant Chemotherapy in Tuboovarian High-grade Serous Carcinoma , 2016, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.
[6] H. Kitchener,et al. Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial , 2015, The Lancet.
[7] A. Tinker,et al. Chemotherapy Response Score: Development and Validation of a System to Quantify Histopathologic Response to Neoadjuvant Chemotherapy in Tubo-Ovarian High-Grade Serous Carcinoma. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] G. Scambia,et al. Prognostic role and predictors of complete pathologic response to neoadjuvant chemotherapy in primary unresectable ovarian cancer. , 2014, American journal of obstetrics and gynecology.
[9] T. Sudo,et al. Histopathology predicts clinical outcome in advanced epithelial ovarian cancer patients treated with neoadjuvant chemotherapy and debulking surgery. , 2013, Gynecologic oncology.
[10] B. Goff. Advanced ovarian cancer: what should be the standard of care? , 2013, Journal of gynecologic oncology.
[11] Song Liu,et al. Histologic parameters predictive of disease outcome in women with advanced stage ovarian carcinoma treated with neoadjuvant chemotherapy. , 2012, Translational oncology.
[12] S. Kehoe,et al. Chemotherapy versus surgery for initial treatment in advanced ovarian epithelial cancer. , 2012, The Cochrane database of systematic reviews.
[13] G. Kenter,et al. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. , 2010, The New England journal of medicine.
[14] P. Morice,et al. Histological response is not a prognostic factor after neoadjuvant chemotherapy in advanced-stage ovarian cancer with no residual disease. , 2009, European journal of obstetrics, gynecology, and reproductive biology.
[15] W. Faught,et al. Histopathologic assessment of chemotherapy effects in epithelial ovarian cancer patients treated with neoadjuvant chemotherapy and delayed primary surgical debulking. , 2007, Gynecologic oncology.
[16] J. Nährig,et al. Histopathologic assessment of tumor regression after neoadjuvant chemotherapy in advanced-stage ovarian cancer. , 2007, Human pathology.
[17] H. Höfler,et al. Histomorphology and grading of regression in gastric carcinoma treated with neoadjuvant chemotherapy , 2003, Cancer.
[18] P. V. van Diest,et al. Effects of chemotherapy on pathologic and biologic characteristics of locally advanced breast cancer. , 1997, American journal of clinical pathology.
[19] M. Kaufmann,et al. Histologische Regression des Mammakarzinoms nach primärer (neoadjuvanter) Chemotherapie , 1994 .
[20] J. Petiot,et al. Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma. Clinicopathologic correlations , 1994, Cancer.
[21] M. Frcsc,et al. Omental Chemotherapy Effects as a Prognostic Factor in Ovarian Cancer Patients Treated With Neoadjuvant Chemotherapy and Delayed Primary Surgical Debulking , 2007, Annals of Surgical Oncology.
[22] A. Taylor,et al. Clinical outcomes of neoadjuvant chemotherapy and primary debulking surgery in advanced ovarian carcinoma. , 2006, European journal of gynaecological oncology.
[23] H. Junkermann,et al. [Histologic regression of breast cancer after primary (neoadjuvant) chemotherapy]. , 1994, Geburtshilfe und Frauenheilkunde.